Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

NCT00423254 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian
Melanoma
Renal
Prostate
Colorectal
Endometrial Carcinoma
Cervical Carcinoma
Testicular Cancer
Thyroid Cancer
Small Cell Lung Carcinoma
Mesothelioma
Breast Carcinoma
Esophageal Carcinoma
Gastric Cancer
Pancreatic Carcinoma
Neuroendocrine Cancer
Liver Cancer
Gallbladder Cancer
Biliary Tract Cancer
Anal Carcinoma
Bone Sarcomas
Soft Tissue Sarcomas
Carcinoma of Unknown Origin, Primary

Interventions

BIOLOGICAL: PSMA/PRAME
BIOLOGICAL: PSMA/PRAME

Sponsor

Mannkind Corporation